肢端肥大症药物治疗进展
收稿日期: 2023-05-31
网络出版日期: 2024-01-09
基金资助
国家重点研发计划项目(2021YFC2501600);国家重点研发计划项目(2021YFC2501601);国家重点研发计划项目(2021YFC2501603);国家自然科学基金重点项目(91857205);国家自然科学基金重点项目(81730023);上海市医药卫生发展基金会糖尿病临床研究项目(Ⅱ期02研究);上海申康医院发展中心促进市级医院临床技能与临床创新能力三年行动计划项目(SHDC2020CR2002A);上海申康医院发展中心促进市级医院临床技能与临床创新能力三年行动计划项目(SHDC2020CR6015);上海市卫生和计划生育委员会科研课题项目(201840049)
Therapy progress for acromegaly
郑思畅, 周薇薇, 王卫庆 . 肢端肥大症药物治疗进展[J]. 内科理论与实践, 2023 , 18(04) : 292 -296 . DOI: 10.16138/j.1673-6087.2023.04.017
| [1] | Colao A, Grasso LFS, Giustina A, et al. Acromegaly[J]. Nat Rev Dis Primers, 2019, 5(1): 20. |
| [2] | Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes[J]. Nat Rev Endocrinol, 2018, 14(9): 552-561. |
| [3] | 中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 751-760. |
| [4] | Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications[J]. Nat Rev Endocrinol, 2010, 6(9): 515-525. |
| [5] | Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas[J]. JAMA, 2023, 329(16): 1386-1398. |
| [6] | Geer EB. Medical therapy for refractory pituitary adenomas[J]. Pituitary, 2023, 26(3): 303-306. |
| [7] | Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly[J]. PLoS One, 2012, 7(5): e36411. |
| [8] | Carmichael JD, Bonert VS, Nu?o M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments[J]. J Clin Endocrinol Metab, 2014, 99(5): 1825-1833. |
| [9] | Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study[J]. J Clin Endocrinol Metab, 2014, 99(3): 791-799. |
| [10] | Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase Ⅲ trial[J]. J Clin Endocrinol Metab, 2015, 100(4): 1699-1708. |
| [11] | Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice[J]. Front Neuroendocrinol, 2013, 34(3): 228-252. |
| [12] | Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly[J]. Endocrine, 2016, 53(1): 210-219. |
| [13] | Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis[J]. J Clin Endocrinol Metab, 2011, 96(5): 1327-1335. |
| [14] | Kuhn E, Chanson P. Cabergoline in acromegaly[J]. Pituitary. 2017, 20(1): 121-128. |
| [15] | Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs[J]. JAMA Intern Med, 2014, 174(12): 1930-1933. |
| [16] | Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly[J]. Endocr Rev, 2002, 23(5): 623-646. |
| [17] | van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist[J]. Lancet, 2001, 358(9295): 1754-1759. |
| [18] | Freda PU, Gordon MB, Kelepouris N, et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY[J]. Endocr Pract, 2015, 21(3): 264-274. |
| [19] | Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly[J]. Pituitary, 2017, 20(1): 129-135. |
| [20] | Fleseriu M, Führer-Sakel D, van der Lely AJ, et al. More than a decade of real-world experience of pegvisomant for acromegaly[J]. Eur J Endocrinol, 2021, 185(4): 525-538. |
| [21] | Bengtsson D, Schr?der HD, Andersen M, et al. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide[J]. J Clin Endocrinol Metab, 2015, 100(4): 1689-1698. |
| [22] | Burman P, Trouillas J, Losa M, et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients[J]. Eur J Endocrinol, 2022, 187(4): 593-605. |
| [23] | Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas[J]. Eur J Endocrinol, 2018, 178(1): G1-G24. |
| [24] | 中国垂体腺瘤协作组. 中国肢端肥大症诊治共识(2021版)[J]. 中华医学杂志, 2021, 101(27): 2115-2126. |
| [25] | Majd N, Waguespack SG, Janku F, et al. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase Ⅱ study[J]. J Immunother Cancer, 2020, 8(2): e001532. |
| [26] | Ilie MD, Villa C, Cuny T, et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study[J]. Eur J Endocrinol, 2022, 187(5): 685-696. |
| [27] | Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly[J]. J Clin Endocrinol Metab, 2013, 98(1): E66-E71. |
| [28] | Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs[J]. J Endocrinol Invest, 2013, 36(1): 38-43. |
| [29] | Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study[J]. Eur J Endocrinol, 2016, 174(2): 241-250. |
| [30] | Chiloiro S, Giampietro A, Mirra F, et al. Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response[J]. Eur J Endocrinol, 2021, 184(2): 217-229. |
| [31] | Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression[J]. J Clin Endocrinol Metab, 2019, 104(3): 915-924. |
| [32] | Venegas-Moreno E, Flores-Martinez A, Dios E, et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly[J]. Cell Mol Med, 2019, 23(5): 3088-3096. |
| [33] | Puig-Domingo M, Gil J, Sampedro-Nu?ez M, et al. Molecular profiling for acromegaly treatment: a validation study[J]. Endocr Relat Cancer, 2020, 27(6): 375-389. |
| [34] | Fusco A, Zatelli MC, Bianchi A, et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas[J]. J Clin Endocrinol Metab, 2008, 93(7): 2746-2750. |
| [35] | Kasuki L, Wildemberg LE, Neto LV, et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern[J]. Eur J Endocrinol, 2013, 169(2): 217-223. |
| [36] | Quabbe HJ, Pl?ckinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly[J]. J Clin Endocrinol Metab, 1989, 68(5): 873-881. |
| [37] | Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly[J]. J Clin Endocrinol Metab, 1996, 81(6): 2356-2362. |
| [38] | Biermasz NR, Pereira AM, Smit JW, et al. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly[J]. Growth Horm IGF Res, 2005, 15(3): 200-206. |
| [39] | Gilbert JA, Miell JP, Chambers SM, et al. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly[J]. Clin Endocrinol (Oxf), 2005, 62(6): 742-747. |
| [40] | Karavitaki N, Botusan I, Radian S, et al. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly[J]. Clin Endocrinol (Oxf), 2005, 62(3): 282-288. |
| [41] | de Herder WW, Taal HR, Uitterlinden P, et al. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly[J]. Eur J Endocrinol, 2005, 153(1): 67-71. |
| [42] | Pokrajac A, Claridge AG, Shakoor SK, et al. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly[J]. Eur J Endocrinol, 2006, 154(2): 267-274. |
| [43] | Carlsen SM, Svartberg J, Schreiner T, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure[J]. Clin Endocrinol (Oxf), 2011, 74(6): 736-743. |
| [44] | Wang M, Shen M, He W, et al. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly[J]. Endocr J, 2016, 63(9): 819-834. |
| [45] | Bandgar TR, Sarathi V, Shivane V, et al. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly[J]. J Postograd Med, 2010, 56(1): 7-11. |
| [46] | Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly[J]. Mayo Clin Proc, 2022, 97(2): 333-346. |
| [47] | Nunes VS, Correa JM, Puga ME, et al. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system[J]. Pituitary, 2015, 18(4): 500-508. |
| [48] | Papaioannou C, Druce M. Preoperative medical treatments and surgical approaches for acromegaly[J]. Clin Endocrinol (Oxf), 2023, 98(1): 14-31. |
| [49] | Puig-Domingo M, Soto A, Venegas E, et al. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice[J]. Endocrinol Nutr, 2016, 63(8): 397-408. |
| [50] | Lim DS, Fleseriu M. The role of combination medical therapy in the treatment of acromegaly[J]. Pituitary, 2017, 20(1): 136-148. |
| [51] | Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR[J]. Pituitary, 2011, 14(2): 148-156. |
| [52] | Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature[J]. Endocr J, 2013, 60(4): 507-515. |
| [53] | Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly[J]. Lancet, 2005, 365(9471): 1644-1646. |
| [54] | Strasburger CJ, Mattsson A, Wilton P, et al. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant[J]. Eur J Endocrinol, 2018, 178(4): 321-329. |
| [55] | Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial[J]. J Clin Endocrinol Metab, 2012, 97(4): 1187-1193. |
| [56] | Bernabeu I, Alvarez-Escolá C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly[J]. Pituitary, 2013, 16(1): 101-108. |
/
| 〈 |
|
〉 |
